Skip to main content Skip to main content
Go to homepage

REN001 in patients with Primary Mitochondrial Myopathy

Safety and Efficacy of REN001 in patients with Primary Mitochondrial Myopathy


Please view complete study details here.

Interested in participating?
We are currently recruiting
Study Sponsor:

Reneo Pharma Ltd

Full IRB Study Title:
A double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 weeks treatment with RNE001 in patients with primary mitochondrial myopathy
IRB Study ID:
If you are interested in this study or have questions about your child's eligibility, please contact:

Hilary Tonni;; 220-543-4734

Lead Investigator
Bruce H. Cohen, MD, FAAN

Chair, NeuroDevelopmental Science Center; Philip H. Maynard Chair in NeuroDevelopmental Science Fund; Chairman, American Academy of Neurology Advocacy Committee; Pediatric Neurologist
Pediatric Brain Tumor ProgramPediatric NeurologyMitochondrial Center

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.